Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04238988 | Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer(MITO CERV 3) | unknown | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT03040791 | Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)(ImmunoProst) | unknown | Phase 2 | 38 | Hospital Moinhos de VentoOTHER |
| 1 |
| Aug 26, 2021 |
| clinicaltrials |
| NCT05016973 | A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer | unknown | Phase 2 | 25 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT03050866 | Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)(CABA-V7) | unknown | Phase 2 | 140 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT05001763 | Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy | unknown | Phase 2 | 160 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | unknown | Phase 2 | 46 | Hunan Cancer HospitalOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge(MITO36) | unknown | Phase 2 | 64 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04995016 | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma(PANDORA) | unknown | Phase 2 | 18 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04985110 | Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital | unknown | Phase 2 | 78 | Indonesia UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04973904 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04958473 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer(SAARCC) | unknown | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04926155 | The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 234 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT04918628 | Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer(CRTCP) | unknown | Phase 2 | 50 | Taizhou HospitalOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04836663 | A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors | unknown | Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04395612 | Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer(CQGOG0101) | unknown | Phase 2 | 38 | Chongqing University Cancer HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04556539 | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | unknown | Phase 2 | 104 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT00703105 | Ovarian Dendritic Cell Vaccine Trial | unknown | Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04828616 | Study of DP303c Injection in Patients With Advanced Ovarian Cancer | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04815408 | PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04800978 | Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 0 | Mar 16, 2021 | clinicaltrials |
| NCT04789941 | How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix | unknown | Phase 2 | 50 | Assiut UniversityOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT03808857 | A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive | unknown | Phase 2 | 80 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02944201 | Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate | unknown | Phase 2 | 22 | Montefiore Medical CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04736108 | Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 50 | West China HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03432780 | Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer(QRT-SOGUG) | unknown | Phase 2 | 134 | Spanish Oncology Genito-Urinary GroupOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04714697 | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 201 | Asan Medical CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT04622761 | Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome(CHROME) | unknown | Phase 2 | 120 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | unknown | Phase 2 | 8 | Kidney Cancer Research BureauOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04664244 | Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | unknown | Phase 2 | 43 | Lei LiOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01835977 | Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer | unknown | Phase 2 | 106 | Clinical Research Office of the Endourological SocietyOTHER | 0 | Dec 16, 2020 | clinicaltrials |
| NCT04661696 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | unknown | Phase 2 | 75 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04651946 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | unknown | Phase 2 | 400 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer(ANNIE) | unknown | Phase 2 | 40 | Jihong LiuOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01505075 | Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer(pHART8) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01953055 | SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)(SATURN) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 27, 2021source: clinicaltrials